Last updated on July 2019

Study of the Safety Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis


Brief description of study

This is a randomized, double-blind, vehicle-controlled, Phase 2 study in subjects with moderate AD.

Detailed Study Description

This is a randomized, double-blind, vehicle-controlled, Phase 2 study in subjects with moderate AD. Eligible subjects will be enrolled and randomized to treatment with BTX 1204 or Vehicle for 84 days. Approximately two hundred (200) subjects will be enrolled. Subjects will receive BID application of study drug for 84 days with a final application on the evening of Day 84 for a total of 168 doses.

Clinical Study Identifier: NCT03824405

Find a site near you

Start Over

Clinical Science Institute

Santa Monica, CA United States
  Connect »

Troy Sullivan

North Miami Beach, FL United States
  Connect »

DS Research

Louisville, KY United States
  Connect »

Delright Research

New Orleans, LA United States
  Connect »

Medisearch Clinical Trails

Saint Joseph, MO United States
  Connect »

Washington Univerisy in St. Louis

Saint Louis, MO United States
  Connect »

JDR Dermatology Research LLC

Las Vegas, NV United States
  Connect »

Greenville Dermatology, LLC

Greenville, SC United States
  Connect »

Dermresearch Inc

Austin, TX United States
  Connect »

J&S Studies Inc.

College Station, TX United States
  Connect »

Sinclair Dermatology

East Melbourne, Australia
  Connect »

The Skin Hospital

Westmead, Australia
  Connect »

P3 Research

Wellington, New Zealand
  Connect »